SUMMARY
The experimental drug used in this study is called Daratumumab.
The purpose of this study is to see if Daratumumab is useful for treating patients with relapsed or refractory Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), or Follicular Lymphoma (FL). Another purpose of the study is to see if certain patients respond to Daratumumab treatment better than others. The safety of Daratumumab will also be studied.
The experimental drug used in this study is called Daratumumab.
The purpose of this study is to see if Daratumumab is useful for treating patients with relapsed or refractory Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), or Follicular Lymphoma (FL). Another purpose of the study is to see if certain patients respond to Daratumumab treatment better than others. The safety of Daratumumab will also be studied.
There are 2 stages in this study. The 1st stage is to determine if Daratumumab may work for your type of cancer (lymphoma). If there is possibility that Daratumumab may work, then the study will proceed to stage 2. If not, the study will end for that cancer type.
COH Protocol Number : 15182
ClinicalTrials.gov Number : NCT02413489
Principal Investigator : Popplewell, Leslie M.D.
Sponsor : Janssen Research & Development
BRIEF ELIGIBILITY CRITERIA :
Eligible Ages : >=18
Gender : Either
Minimum Performance Status : ECOG/SWOG:1
Treatment Intent : Non-Adjuvant treatment
Prior Chemotherapy :
Brain Metastases :
Measurable Disease :
